Abstract
Background: Opicapone (OPC) proved effective in treating end-of-dose motor fluctuations in Parkinson's Disease (PD) patients in two pivotal trials (BIPARK-I and II). This real-world clinical practice study evaluated OPC 50-mg in a heterogeneous population of PD patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
